Notice Number: NOT-CA-15-041
Key Dates
Release Date: November 2, 2015
RFA-AG-16-020
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in RFA-AG-16-020, "Impact of Aging on Currently Employed Animal Models of Disease and Chronic Conditions: Demonstration Projects (UH2/UH3)."
The following sections of RFA-AG-16-020 have been updated to reflect NCI's participation in this Funding Opportunity Announcement.
Part 1. Overview Information
Components of Participating Organizations
National Institute on Aging (NIA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Environmental Health Sciences (NIEHS)
National Cancer Institute (NCI)
Catalog of Federal Domestic Assistance (CFDA) Numbers
93.866, 93.396, 93.855, 93.121, 93.853, 93.113, 93.856
Part 2. Section I. Funding Opportunity Description
Institute-Specific Areas of Interest
NCI
NCI is interested in supporting pilot studies that utilize murine models of human cancers to assess whether the chronological age of the animal model is a critical factor in understanding the pathobiology of disease or response to intervention. Successful fulfillment of this FOA will lay the foundation for elucidating the mechanisms by which aging influences cancer development and response to therapy in basic and translational cancer research. Note that this RFA is limited to the expansion and aging of murine models in which the cancer can be induced at a later time point than is typically used for that specific model. NCI will not support the generation of new murine models or complex breeding programs. Murine models considered responsive must:
- represent models of strongly age-related human cancers;
- have been reported/described in peer-reviewed literature;
- be inducible. Examples of inducible models include, but are not limited to, genetically engineered mouse models (GEMMs) that conditionally regulate the expression of oncogenes and/or tumor suppressors or induction regimens that utilize chemical carcinogens or irradiation;
- parallel human cancer progression (i.e., the cancer modeled in a murine model should mimic the human counterpart;
- compare the effects of cellular transformation on cancer progression in old versus young mice and its correlation to human systems;
In addition:
- The ability to assess therapeutic outcomes in aged versus young adult murine models of human cancers would add significant value to the proposal. Only therapeutic approaches typically used (and reported in the literature) for each specific murine model is allowable. This FOA will not support the development of new therapeutic approaches.
- Applicants must define the aged time point at which the disease process (and therapeutic approach if appropriate) will be induced and studied. Aged time points for both male and female mice should be justified.
Section II. Award Information
The National Cancer Institute (NCI) intends to commit an estimated total of $375,000 in FY2016 to fund 6 awards (2 of those 6 co-funded by the NIA).
Part 2. Section VII. Agency Contacts
Scientific/Research Contact(s)
Susan McCarthy, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6200
Email: [email protected]
Financial/Grants Management Contact(s)
Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
Email: [email protected]
Inquiries
Please direct all inquiries to:
Susan McCarthy, Ph.D.
National Cancer Institute (NCI)
Telephone: 240- 276-6200
Email: [email protected]
and Human Services (HHS)
